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family that are expressed only on professional APCs and are important in the early interactions
between APCs and T cells during the induction of immune response. It is well established that
mCD86 is expressed by AML blasts in a considerable proportion of patients. The release of soluble
forms of membrane molecules provides a powerful means by which leukocytes can either inhibit or
enhance the biological effects relative of their membrane-bound counterparts, and there is now con-
siderable evidence to support the possibility that the release of a soluble form of CD86 (sCD86) has
an immunoregulatory role in vivo. The observation that sCD86 levels are highest in the FAB sub-
types with the highest AML blast levels, together with the observation that high levels of sCD86 are
associated with poor prognosis, strongly suggests that sCD86 is derived from the malignant cells in
these patients.
The aim: The present study was to assess levels of sCD86 in de novo acute myeloid leukemia
patients and to determine any possible correlation with outcome following induction chemotherapy.1605847.
(D. Nafee).
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26 N. Hamed et al.The study was carried out on 30 patients with de novo acute myeloid leukemia and 20 healthy
controls.
Method: Levels of soluble CD86 (sCD86) in the serum was measured using ELISA technique at
presentation and after one cycle of induction chemotherapy.
Conclusion: We found that sCD86 was detected in both patients and controls. Levels of sCD86
were higher than the cut-off value in 36.6% of patients. There was a signiﬁcant difference between
levels of sCD86 before and after treatment. Patients (54.5%) with high sCD86 levels had monocytic
morphology. Patients with high levels of sCD86 had a lower rate of complete remission.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Acute myelogenous leukemia represents a group of clonal
hematopoietic stem cell disorders that result from genetic alter-
ations in normal hematopoietic stem cells. These alterations in-
duce differentiation arrest and/or excessive proliferation of
abnormal leukemic cells or blasts.1,2
The generation of both humoral immune responses (by B
cells) and cell mediated cytotoxicity (by cytotoxic T (Tc) cells)
depends on the activation of CD4+ T helper cells (TH). Initial
TH cell activation is initiated by the interaction of the TCR–
CD3 complex with the processed antigenic peptide bound to
class II MHC molecule on the surface of an APC (antigen pre-
senting cell).3
Activation of resting TC involves ﬁrst of all TCR stimuli
and then secondly stimulation with cytokines, especially IL-
2, most probably from activated TH cells.
4
All naı¨ve T cells require two signals to initiate an immune
response. Signaling through the T cell-antigen receptor in the
absence of a costimulatory signal may or may not affect T
cells. The principal costimulatory molecule is CD28, a receptor
that is constitutively expressed on the surface of nearly all
CD4+ TH cells and the majority of CD8
+ TC cells. When both
the TCR and CD28 bind to their ligands at the same time, their
respective intracellular signals act synergistically to activate the
cell’s replicative machinery and secretory apparatus.5,6
Successful delivery of signal 2 implicates migration of a
coinhibitory receptor called CTLA-4 from its subcellular Golgi
compartment to the T cell plasma membrane. CTLA-4 is nor-
mally not present to any signiﬁcant degree in the inactive T cell
membrane, competes with CD28 for its ligands (B7.1 and B7.2),
and sends a turn off signal to the T cell. Therefore, the newly
activated T cell has to manage two contradictory communica-
tions: an early activation/proliferation message from CD28
and a delayed deactivation/nonproliferation message from
CTLA-4. Evidence suggests that when B7.1 and B7.2 bind to
their receptors, signals are generated in both directions: into
the APC and into the T cell, affecting both cells.7,8
The expression of the B7 antigens, B7.1(CD80) and B7.2
(CD86), is tightly regulated.9
Unstimulated antigen presenting cells are largely B7.2 neg-
ative and B7.1 negative.10–12
After activation, dendritic and epidermal Langerhans’ cells,
B cells, and macrophages upregulate the expression of B7.2
and B7.1. In addition to their expression on MHC class
II-bearing cells, B7.2 is expressed on granulocytes, B7.1 on
ﬁbroblasts, and both molecules are present on activated mur-
ine and human T cells.10,11,13This pattern of expression raises the possibility that B7 mol-
ecules may have other functions in addition to the costimula-
tion of T cells. Several cytokines modulate the expression of
B7.1 and B7.2, including IL-10, IL-4, granulocyte–macro-
phage colony stimulating factor, and interferon-c.10
Some investigators have suggested that CD80 and CD86
provide similar costimulatory signals for T cell proliferation
and cytokine production,14,15 others demonstrated that they
produce contrasting effects.16,17
While other studies found that CD80 could negatively reg-
ulate T cell activation induced by either mitogens or speciﬁc
antigens, while CD86 can positively regulate T cell activation
through CD28-mediated signals.18–20
The reasons for the differences seen in costimulatory signals
initiated by CD80 and CD86 are not fully known. One critical
determinant could be the differences in the peak expression of
CD80/CD86/CD28/CTLA-4. Both CD86 and CD28 are con-
stitutively expressed in high levels, whereas CD80 and
CTLA-4 expression is induced, and their surface expression
peaks 24–48 h after induction.21,22
Because of their various modulatory functions, probably
for and against tumor immunity, the pathologic roles of B7
family molecules expressed by human tumor cells are of great
interest. Serum levels of sCD86 were found to be signiﬁcantly
elevated in patients with multiple myeloma and were associ-
ated with a shorter survival.23
In acute myeloid leukemia, it was reported that leukemic
cells from a substantial number of patients expressed B7.2.24–27
However, conﬂicting results exist whether such patients are
associated with poor prognosis. There are a number of mech-
anisms by which tumors may actively evade or silence/suppress
an immune response. Direct deletion of immune effector cell
by expression of death-inducing ligands. (B) Direct tolerization
of tumor-reactive T cells. (C) Suppression of tumor-reactive T
cells by regulatory T cells. (D) Ignorance of tumor as a result
of spatial separation of T and tumor cells. (E) Tolerization of
host T cells by cross-presentation of tumor-derived antigens.27
The aim of the study is to assess the level of soluble CD86
level (sCD86) in patients with de novo AML and determine
any possible correlation with treatment outcome.2. Methods
The study was carried out on 50 subjects:
Thirty adult patients with de novo acute myeloid leukemia.
Their ages ranged between 16 and 55 years with a mean value
of 31.7 ± 13.76 years selected from patients admitted to the
AML, APC, sCD86 27Hematology Unit, Alexandria Main University Hospital and
20 healthy adult persons (volunteers) age and sex matched as
controls.
The study was approved by the Research Ethics Committee
(REC) of Alexandria University and a written informed con-
sent was obtained from all patients participating in the study.
On admission, patients included in the study were subjected
to the following:
1. Full history taking
2. Thorough clinical examination
3. Routine investigations:
A. Biochemical tests including:
- Liver function tests, renal function tests, LDH, uric acid.
B. Radiological Imaging:
- Echocardiography before starting chemotherapy.
- Plain X-ray chest, ultrasound abdomen.
4. Hematological assessment:
- Complete blood picture.
- Bone marrow examination with morphological exami-
nation and immunophenotyping for diagnosis.
- Peripheral blood samples were taken before and after
chemotherapy for assessment of sCD86 from AML pa-
tients and from control.
All patients received induction chemotherapy in the form of
cytosine arabinoside (100 mg/m2) for seven days and
doxorubicin (25 mg/m2) for 3 days.
2.1. Exclusion criteria
All patients with the following criteria were excluded from the
study:
 Patients aged <16 years or >60 years.
 Patients with signiﬁcant renal, hepatic or cardiac impair-
ment that prevented them from receiving full dose of induc-
tion chemotherapy.
 Patients with FAB subtype M3 (patients did not receive the
standard 3 + 7 chemotherapy protocol).
2.2. Assessment of sCD86
Peripheral blood samples were taken before starting chemo-
therapy. Control samples were obtained from 20 healthy
individuals who volunteered to give their samples. 2 ml of
venous blood were withdrawn into plain vacutainer tubes,
allowed to clot for 10 min at room temperature. Samples
then were centrifuged for 10 min. Sera were removed and
stored at 20 C until processed for estimation of the serum
soluble CD86 by enzyme linked immunosorbent assay
(ELISA).33,34
2.3. Cut-off value for sCD86
The cut off value was 40 l/ml. Patients with levels equal to or
above cut off value were deﬁned as sCD86 positive, while pa-
tients with levels of sCD86 below cut off value were deﬁned as
sCd86 negative.2.4. Statistical methods
Data (expressed as mean and standard deviation) entry to the
computer was done followed by tabulation and analysis. Anal-
ysis was done using SPSS-15 (Statistical Package for Social
Sciences version 15).
Correlation between sCD86 and other parameters was done
using Pearson correlation. Comparison of sCD86 levels before
and after treatment was done using paired t-test.3. Results
The study was focused on 30 adult patients with de novo AML
admitted to the Hematology department, Alexandria Main
University Hospital. Their ages ranged between 16 and
55 years with a mean value of 31.7 ± 13.76 years. They were
15 males (50%) and 15 females (50%) and 20 healthy adult
persons as a control group, their ages ranged between 16 and
50 years with a mean of 32.5 ± 9.89 years. They were 11 males
(55%) and nine females (45%).
As regards the distribution of FAB subtypes among pa-
tients; two patients were M0 representing 6.7%, 12 patients
were M2 representing 40%, four patients were M1 representing
13.3%, seven patients were M4 representing 23.3%, ﬁve pa-
tients were M5 representing 16.6%, with no cases M6 or M7.
As regards the clinical outcome after the ﬁrst cycle of che-
motherapy, 11 patients achieved CR (36.7%) and 19 patients
did not achieve CR (63%).
Soluble CD86 WAS DETECTED in the plasma of all nor-
mal controls and patients included in the study. Levels of
SCD86 in the patients ranged from 6.6 to 96.1 lL/ml with a
mean of 39.44 ± 27.08. In control Levels of SCD86 ranged
from 3 to 29.4 lL/ml with a mean of 14.46 ± 8.49. There
was signiﬁcant difference between the levels detected in normal
control and patients p= 0.001. (Table 1)
As regards the positivity for soluble CD86, 19 patients
(63.3%) were negative and 11 patients (36.7%) were positive
(Fig. 1).
Among 30 AML patients (2 were FABM0 6.7%, 4 FABM1
13.3%, 12 FABM2 40%, 12 FABM4 and M5 40%). Complete
remission was achieved in (one patient FABM0 9.1%, 1
FABM1 9.1%, 2 FABM2 27.3%, 6 FABM4 & M5 54.5%)
(Table 2).
Soluble CD86 (sCD86) was detected in the plasma of all
normal controls and patients included in the study. In AML
patients: Levels of sCD86 ranged from 6.6 to 96.1 U/ml with
a mean of 39.44 ± 27.08.While in the control group, levels
of sCD86 ranged from 3 to 29.4 U/ml with a mean
14.46 ± 8.49. There was a signiﬁcant difference between the
levels detected in normal controls and levels detected in pa-
tients (P= 0.001). There was also a signiﬁcant difference be-
tween sCD86 levels in patients before and after treatment
(P= 0.0001) (Fig. 2).
Distribution of sCD86 positivity among the different FAB
subtypes demonstrated that 54.5% of sCD86 positive patients
(6 of 11) had monocytic morphology (M4 and M5) and 45.5%
(5 of 11) had non monocytic morphology.
There was a signiﬁcant positive correlation between levels
of sCD86 before treatment and white blood cell counts
(P< 0.05) (Table 3).
Table 1 Levels of sCD86 in AML patients.
Case number sCD86 (U/ml) Control
Before After
1 61 11 29.4
2 20 14.1 23.4
3 39 13.6 21.4
4 9.2 4.8 20.2
5 15.8 7.6 23.4
6 19.4 18 19
7 31 18.4 10
8 66.3 23.6 27.6
9 61 24 3
10 29 15 9.4
11 31 12 5.4
12 39 13 5.2
13 32 12.4 3.8
14 52 21 5
15 96.1 5.4 6.6
16 96 14.6 11.6
17 22.8 13 8.4
18 35.4 27 18
19 40 10.2 19.4
20 89.6 79 19
21 48.8 15
22 6.6 6.4
23 87.3 26.4
24 9.4 5
25 26 14.2
26 20 16.6
27 62 3.4
28 7.2 5
29 11.6 6.4
30 18.6 6
Range 6.6 – 96.1 3.4–79 3–29.4
Mean 39.44 15.4 14.46
S.D 27.08 13.7 8.49
36.7
63.3
Positive
Negative
Figure 1 Distribution of AML patients according to the
positivity for sCD86 before treatment.
Table 2 Relation between outcome and FAB subtype.
Outcome Total
CR No CR
FAB M0 No. 1 1 2
% 9.1% 5.3% 6.7%
M1 No. 1 3 4
% 9.1% 15.8% 13.3%
M2 No. 3 9 12
% 27.3% 47.4% 40%
M4 and M5 No. 6 6 12
% 54.5% 31.6% 40%
Total No. 11 19 30
% 100% 100% 100%
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Figure 2 Comparison between levels of sCD86 (before and after
treatment) and control group.
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sCD86 positive patients 27.3% (3 of 11) achieved complete
remission while 72.7% (8 of 11) did not achieve complete
remission. While among sCD86 negative patients, 42% of pa-
tients (8 of 19) achieved complete remission and 57.9% (11 of
19) did not achieve complete remission.
The one year overall survival among CD86 positive patients
seven survived (63.6%) and four died (36.4%), while CD86
negative patients 14 died (73.7%) and ﬁve survived (26.3%).4. Discussion
The aim of the present study was to evaluate the levels of sol-
uble CD86 (sCD86) levels in patients with de novo acute mye-
loid leukemia and whether this may be correlated with
treatment outcome.
The study was performed on thirty adult patients with de
novo acute myeloid leukemia (and 20 healthy controls, age
and sex matched.
Levels of sCD86 were determined in AML patients, levels
were measured again after the ﬁrst cycle of induction chemo-
therapy for follow up in an attempt to ﬁnd any possible corre-
lation with outcome.
In the current study, sCD86 levels were detected in the sera
of patients with de novo AML before and after administration
of induction chemotherapy as well as in the sera of normal
controls.
Levels of sCD86 in patients before chemotherapy ranged
from 6.6 to 96.1 U/ml with a mean 39–44 ± 27.08 U/ml.
Levels of sCD86 in controls ranged from 3 to 29.4 U/ml with
a mean value of 14.46 ± 8.49 U/ml.
The majority of patients (63.3%) had sCD86 levels similar
to that of normal controls. Our observations were consistent
with Hock et al. who found that 75% of their patients having
sCD86 levels within the range observed in normal donors.28
Levels of sCD86 were signiﬁcantly higher in patients before
treatment in comparison to controls (p= 0.0001).
Table 3 Correlation coefﬁcient between level of sCD86 before
and after treatment and white blood cells.
sCD86 before sCD86 after
WBCs r 0.374(*) 0.121
p 0.042 0.525
* Denotes signiﬁcant correlation.
AML, APC, sCD86 29Level of sCD86 was signiﬁcantly higher in patients before
treatment than after treatment (p= 0.001).
Level of sCD86 in patients in remission was normal. This
result is in agreement with that achieved by Hock et al.29 in
their study suggesting that at least in some AML patients,
sCD86 levels may reﬂect disease status. Hock et al. also ana-
lyzed the changes in sCD86 levels during treatment and found
that levels of sCD86 steadily declined following commence-
ment of chemotherapy becoming normal by the time of ﬁrst
remission.
With respect to CD86, the release of a soluble form pro-
vides a potentially powerful mechanism by which cells may
modulate the co-stimulatory signals delivered though
mCD86.28 Both APC and AML blasts express sCD86 tran-
script and mCD86 protein; thus both cell types provide a po-
tential source of the elevated sCD86 levels observed in some
patients. The observation that sCD86 levels are highest in
the FAB subtypes with the highest AML blast levels of
mCD86 expression, together with the observation that high
levels of sCD86 are associated with poor prognosis, strongly
suggests that sCD86 is derived from the malignant cells in
these patients.29,30
Hollsberg and Kapsogeorgou et al. reported that a number
of cell types express functionally distinct forms of CD86 prob-
ably as a result of changes in glycosylation status. It is there-
fore possible that sCD86 generated by APC and AML blasts
may differ functionally.31,32
In the current study, distribution of sCD86 levels among
the different FAB subtypes showed that 54.5% of sCD86 po-
sitive patients had monocytic morphology (M4 and M5) and
45.5% had non monocytic morphology. These results are sim-
ilar to the results observed by Hock et al. in their study dem-
onstrating that 76% sCD86 positive patients had monocytic
morphology.
APC expression of CD40, adhesion molecule, and (most
importantly) B7 molecules is critical for the induction of im-
mune responses. This led to the concept that tumor cells escape
immunosurveillance because they lack expression of these mol-
ecules. However, in AML, many of the blast cells, particularly
those of the FAB M4–M5 subtype, have an APC-like pheno-
type, and a number of studies have now reported that high
expression of CD40, adhesion molecule, or CD86 molecules
is associated with poor prognosis. These ﬁndings suggest
APC and malignant cells and/or that other mechanisms regu-
late the function of these molecules in a malignant setting.33–35
White blood cell counts in sCD86 negative patients had a
mean of 32.337 ± 56.2202 (·109/L), while in sCD86 positive
patients, white blood cell counts had a mean of 70.509 ±
74.5899 (·109/L). Although white blood cell counts in sCD86
positive patients were higher than in sCD86 negative patients,
this difference was not statistically signiﬁcant. However, levels
of sCD86 in AML patients before treatment were signiﬁcantly
positively correlated with leukocyte counts.Tamura et al.36 reported in their study that sCD86 positive
AML patients had a signiﬁcantly higher leukocyte count com-
pared with the sCD86 negative patients (p= 0.026), these re-
sults suggesting that sCD86 may be related to the increase in
leukemic cells in the hosts. The ﬁnding that sCD86 (B7.2)
was associated with hyperleukocytosis in their patients sug-
gested that expression of these molecules might contribute to
the proliferation of AML cells by helping them evade anti-
tumor immune responses.
On comparing the outcome in relation to sCD86 in the cur-
rent study, 27.3% of sCD86 positive patients had achieved
complete remission following induction chemotherapy. In
sCD86 negative patients, 42% had complete remission. CR
rate was lower in positive sCD86 patients than sCD86 negative
patients; however these differences were not statistically
signiﬁcant.
This observation was similar to that demonstrated by Hock
et al.28 who found that in patients younger than 60 years,
sCD86 levels provided an prognostic marker independent of
cytogenetics and leukocyte count. However, Tamura et al.36
did not ﬁnd B7.2 expression an independent prognostic factor
in their study.
These results were different from those reported by Hock
et al.28 They demonstrated that AML patients 60 years and
younger with high levels of sCD86 tended to have a shorter
survival compared with patients with normal sCD86, although
this difference was not signiﬁcant. Their analysis indicated that
increased sCD86 levels were associated with poor survival.
Although the presence of elevated sCD86 levels was associated
with FAB M4–M5 subtypes, these patients did not have a sig-
niﬁcantly different survival compared with patients who had
non–FAB M4–M5 subtypes. However, as the number of pa-
tients was small, this result must be treated with caution until
it is validated in a larger patient group.
In their study, Hock et al. demonstrated that in patients
older than 60 years, there was no signiﬁcant difference in the
survival of patients with normal sCD86 levels and patients
with high sCD86 levels. This ﬁnding does not preclude a role
for sCD86 in these patients but may reﬂect the presence of
other independent factors that have a stronger inﬂuence on
outcome.
The difference between results of the current study and the
other studies regarding the possible correlation between levels
of sCD86 and survival could be attributed to the fact that the
major cause of death in our patients was sepsis and some pa-
tients died during aggressive consolidation cycles after achiev-
ing complete remission. Also in some patients, the
incompliance of the patients themselves in follow up caused
some of them to be delayed in receiving their consolidation
with subsequent relapse or death due to the complications
of relapse without enough time for them to receive
consolidation.
Antitumor T cell mediated speciﬁc immune responses re-
quire well organized, multiple steps of molecular interaction
of MHC molecules on APCs (professional APCs and/or tu-
mor cells), presentation of tumor speciﬁc peptides in optimal
amounts by MHC molecules, optimal costimulatory signals,
intact T cell-receptor associated signal mechanisms, and the
presence of an appropriate cytokine milieu. When one of
these steps becomes deranged, the immune response against
tumor cells may become insufﬁcient. In patients who have
developed a malignancy, the malignant cells have evaded
30 N. Hamed et al.antitumor immunity using mechanisms that are probably
diverse even among patients with the same malignant
disease.
References
1. Stone RM. AML: current landscape and future directions.
Hematology (Am Soc Hematol Educ Progam). Hematology
2004:98–117.
2. Pazdur R, Coia LR, Hoskins WJ. Acute leukemias. CMP
Healthcare Media, Oncology Publishing Group, 2004:747–772.
3. Alarcon B, Gil D, Delgado P, Schamel WW. Initiation of TCR
signaling: regulation within CD3 dimers. Immunol Rev
2003;191:38–46.
4. Goldsby RA, Kindt TJ, Osborne BA, Kuby J. in: Freeman WH
(editor) Immunology. 5th ed. 2003.
5. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T
cell costimulation. Annu Rev Immunol 1996;14:233–58.
6. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited.
Annu Rev Immunol 2005;23:515–48.
7. Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces
immunostimulatory signals in dendritic cells via CD80 and CD86.
Nat Immunol 2004;5:1134–42.
8. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates
tryptophan catabolism in vivo. Nat Immunol 2002;3:1097–101.
9. Linsley PS, Greene JL, Brady W, et al. Human B7–1 and B7–2
bind with similar avidities but distinct kinetics to CD28 and
CTLA-4 receptors. Immunity 1994;1:793–801.
10. Guinan EC, Gribben JG, Freeman GJ, et al. Pivotal role of the
B7: CD28 pathway in transplantation tolerance and tumor
immunity. Blood 1994;84:3261–82.
11. Razi-Wolf Z, Freeman GJ, Galvin F, et al. Expression and
function of the murine B7 antigen. The major costimulatory
molecule expressed by peritoneal exudates cells. Proc Natl Acad
Sci USA 1992;89:4210–4.
12. Inaba K, Witmer-Pack M, Inaba M, et al. The tissue distribution
of the B7–2 costimulator in mice. abundant expression on
dendritic cells in situ and during maturation in vitro. J Exp Med
1994;180:1849–60.
13. Reiser H, Schneeberger EE. Expression and function of B7–1 and
B7–2 in hapten-induced contact sensitivity. Eur J Immunol
1996;26:880–5.
14. Lanier LL, O’Fallon S, Somoza C, et al. CD80, CD86 provide
similar costimulatory signals for T cell proliferation, cytokine
production, generation of CTL. J Immunol 1995;154:97.
15. Schweitzer AN, Borriello F, Wong RC, Abbas AK, et al. Role of
costimulators in T cell differentiation: studies using antigen-
presenting cells lacking expression of CD80 or CD86. J Immunol
1997;158:2713.
16. Freeman GJ, Boussiotis VA, Anumanthan A, et al. B7–1, B7–2 do
not deliver identical costimulatory signals. Immunity 1995;2:523.
17. Matulonis U, Dosiou C, Freeman G, et al. B7-1 is superior to B7-
2 cosstimulation in the induction and maintenance of T cell
mediated antileukemia immunity. J Immunol 1996;156:1126.
18. Boulougouris G, Mcleod JD, Patel YI, et al. Positive and negative
regulation of human T cell activation mediated by the CTLA-4/
CD28 ligand CD80. J Immunol 1998;161:3919.
19. Inobe M, Aoki N, Linsley PS, et al. The role of the B7–1a
molecule, an alternatively spliced form of murine B7–1, on T cell
activation. J Immunol 1996;157:582.20. Chai JG, Vendetti S, Amofah E, Dyson J, Lechler R. CD152
ligation by CD80 on T cells is required for the induction of
unresponsiveness by costimulation deﬁcient antigen presentation.
J Immunol 2000;165:3037.
21. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T
cell costimulation. Annu Rev Immunol 1996;14:233.
22. Greenﬁe EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation:
a review. Crit. Rev. Immunol. 1998;18:389.
23. Hock BD, Drayson M, Patton WN, et al. Circulating levels,
clinical signiﬁcance of soluble CD86 in myeloma patients. Br J
Haematol 2006;133:165.
24. Maeda A, Yamamoto K, Yamashita K, et al. The expression of
co-stimulatory molecules and their relationship to the prognosis of
human acute myeloid leukaemia: poor prognosis of B7–2-positive
leukaemia. Br J Haematol 1998;102:1257–62.
25. Costello RT, Mallet F, Sainty D, Maraninchi D, Gastaut JA,
Olive D. Regulation of CD80/B7–1 and CD86/B7–2 molecule
expression in human primary acute myeloid leukemia and their
role in allogenic immune recognition. Eur J Immunol
1998;28:90–103.
26. Whiteway A, Corbett T, Anderson R, Macdonald I, Prentice HG.
Expression of co-stimulatory molecules on acute myeloid leukae-
mia blasts may effect duration of ﬁrst remission. Br J Haematol
2003;120:442–51.
27. Tamura H, Tamada K, Nakamura K, et al. Expression of
functional B7–H2 and B7.2 co-stimulatory molecules and their
prognostic implications in de novo acute myeloid leukemia.
Clinical Cancer Res 2005;11:5708–17.
28. Hock BD, Mckenzie JL, Patton WN, et al. The clinical signiﬁ-
cance of soluble CD86 levels in patients with acute myeloid
leukemia and myelodysplastic syndrome. Cancer 2003;98:1681–8.
29. Hock BD, Patton WN, Budhia S, et al. Human plasma contains a
soluble form of CD86 which is present at elevated levels in some
leukemia patients. Leukemia 2002;16:865–73.
30. Jeannin P, Magistrelli G, Aubrry JP, et al. Soluble CD86 is a
costimulatory molecule for human T lymphocytes. Immunity
2000;13(3):303–12.
31. Hollsberg P, Scholz C, Andersen DE, et al. Expression of a
hypoglycosylated form of CD86 on human T cells with altered
binding properties to CD28 and CTLA-4. J Immunol
1997;159:4799–805.
32. Kapsogeorgou EK, Moutsopoulos HM. Manoussakis Mn. Func-
tional expression of a costimulatory B7.2 (CD86) protein on
human salivary gland epithelial cells that interacts with the Cd28
receptor, but has reduced binding to CTLA-4. J Immunol
2001;166:3107–13.
33. Brouwer RE, Hoefnagel J, Borger van Der Burg B, et al.
Expression of co-stimulatory and adhesion molecules and chemo-
kine or apoptosis receptors on acute myeloid leukemia. Br J
Haematol 2001;115:298–308.
34. Heaney Ml, Golde DW. Soluble cytokine receptors. Blood
1996;87:847–57.
35. Maeda A, Yamamoto K, Yamashita K, et al. The expression of
co-stimulatory molecules and their relationship to the prognosis of
human acute myeloid leukaemia: poor prognosis of B7–2-positive
leukaemia. Br J Haematol 1998;102:1257–62.
36. Tamura H, Tamada K, Nakamura K, et al. Expression of
functional B7–H2 and B7.2 co-stimulatory molecules and their
prognostic implications in de novo acute myeloid leukemia.
Clinical Cancer Res 2005;11:5708–17.
